Personalized Cancer Risk Assessment for Nasopharyngeal Cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study helps doctors predict which patients with nasopharyngeal cancer (a cancer of the upper throat) will benefit most from additional chemotherapy after radiation treatment. It uses a special blood test and imaging to create a personalized risk score for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Confirmed nasopharyngeal cancer (non-keratinizing type) that has not spread to distant parts of the body
- Good overall health status and adequate organ function (liver, kidneys, blood counts)
- High-quality imaging scans (MRI) and blood tests for EBV DNA done before any treatment
- Able and willing to attend regular follow-up visits and share medical records for research
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests whether a personalized radiation plan for the neck can prevent cancer from spreading in people with nasopharyngeal carcinoma. It's for those whose cancer hasn't spread beyond the head and neck area.
This trial tests whether adjusting chemotherapy based on tumor markers (EBV-DNA) and MRI scans can improve outcomes and reduce side effects for people with nasopharyngeal cancer. If you have stage II or III disease, this study might help guide your treatment more precisely.
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
This study looks at tissue and blood samples from people already treated for nasopharyngeal carcinoma to find markers that predict how well treatment works and to identify new ways to treat the cancer. It may help doctors personalise care in the future.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.